Changes in bone turnover during tibolone treatment

• Published in: Maturitas Vol. 47; no. 2; pp. 83 - 90
• Main Authors: Riera-Espinoza, Gregorio, Ramos, Jenny, Carvajal, Rosalı́a, Belzares, Emma, Stanbury, Guadalupe, Farı́as, Rosa, Valderrama, Inés, Alvarez, Kelia, Riera-González, Gregorio
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 20.02.2004; Elsevier Science
• Subjects: Acid Phosphatase - analysis; Alkaline Phosphatase - analysis; Anabolic Agents - therapeutic use; Biological and medical sciences; Biomarkers - analysis; Bone alkaline phosphatase; Bone Density - drug effects; Bone Density - physiology; Bone markers; Bone Remodeling - drug effects; Collagen - analysis; Collagen Type I; Drug Administration Schedule; Female; Forearm; Genital system. Reproduction; Gynecology. Andrology. Obstetrics; Humans; Isoenzymes - analysis; Medical sciences; Middle Aged; N-telopeptide; Norpregnenes - therapeutic use; Osteoporosis, Postmenopausal - prevention & control; Peptides - analysis; Pharmacology. Drug treatments; Postmenopausal; Puberal and climacteric disorders (male and female); Tartrate-Resistant Acid Phosphatase; Tibolone; Bone alkaline phosphatase; Postmenopausal; N-telopeptide; Bone markers; Tibolone; Steroid; Alkaline phosphatase; Menopause; Diseases of the osteoarticular system; Phosphoric monoester hydrolases; Biological marker; Esterases; Bone disease; Osteoarticular system; Osteoporosis; Enzymatic activity; Female; Human; Enzyme; Chemotherapy; Treatment; Hydrolases; Bone mineral density; Bone; Anabolic agent
• ISSN: 0378-5122; 1873-4111
• DOI: 10.1016/S0378-5122(03)00253-6

Objectives: An open study was carried out to evaluate changes in bone remodeling markers such as N-telopeptide (NTx), tartrate-resistant acid phosphatase (TRAP), total alkaline phosphatase (TAP), and bone alkaline phosphatase (BAP) during a 1-year continuous tibolone treatment in postmenopausal women. Material and methods: Thirty-six postmenopausal women were recruited for receiving tibolone 2.5 mg per day for 1 year. Densitometry and determination of biochemical markers of bone metabolism in serum and urine were performed at 1, 3, 6, and 12 months. Results: Comparing baseline with 12 month's values, BAP and all resorption markers decreased significantly. NTx began to decrease since the initiation of the treatment (baseline: 74.4±5.3; 1 month: 57.5±4.2; 12 months: 36.6±2.8). BAP increased at the first month (baseline: 37.3±2.1; 1 month: 42.6±3.0) but diminished in the following months (12 months: 23.1±1.5). TAP started to decrease significantly only after 6 months of treatment (baseline: 37.3±2.1; 12 months: 31.4±2.3) and TRAP after 3 months (baseline: 9.8±0.4; 6 months: 9.1±0.5; 12 months: 8.2±0.4). Normal bone mineral density at distal and ultradistal forearm was maintained during the 1-year treatment (baseline: 0.42±0.01; 12 months: 0.42±0.01 and baseline: 0.33±0.01; 12 months: 0.33±0.01, respectively). Conclusion: The use of tibolone 2.5 mg per day diminished progressively and significantly bone resorption and formation markers during 1-year treatment period.